Ascentage Pharma Group International - Unsponsored ADR (AAPG) - What Are Researchers Thinking About This Stock?

Key Points

• Analysts are broadly bullish: all 14 covering firms rate Ascentage Pharma positively, including 12 “buy” and two “strong buy” recommendations. The average 12-month price target is $43.90.
• Recent coverage includes targets ranging from $33 to $48, with JPMorgan lowering its target to $33 while Citigroup initiated coverage with a $46 target and BTIG maintained a $48 objective.
• AAPG opened at $14.69, near its one-year low of $14.45 and below its 50-day and 200-day moving averages. The company reported a quarterly loss of $0.65 per share on $22.24 million in revenue, and analysts expect a full-year loss of $2.42 per share.

Shares of Ascentage Pharma Group International - Unsponsored ADR (NASDAQ:AAPG - Get Free Report) have earned a consensus recommendation of "Buy" from the fourteen ratings firms that are currently covering the company, MarketBeat reports. Twelve research analysts have rated the stock with a buy recommendation and two have given a strong buy recommendation to the company. The average 12 month target price among brokers that have covered the stock in the last year is $43.90.

AAPG has been the subject of several recent research reports. Citizens Jmp initiated coverage on Ascentage Pharma Group International in a report on Tuesday. They set a "market outperform" rating and a $35.00 price target for the company. Citigroup assumed coverage on shares of Ascentage Pharma Group International in a report on Tuesday. They issued a "buy" rating and a $46.00 target price on the stock. JPMorgan Chase & Co. dropped their price target on shares of Ascentage Pharma Group International from $46.00 to $33.00 and set an "overweight" rating on the stock in a research note on Thursday, October 8th. William Blair assumed coverage on Ascentage Pharma Group International in a research note on Friday. They set an "outperform" rating for the company. Finally, BTIG Research reaffirmed a "buy" rating and set a $48.00 price objective on shares of Ascentage Pharma Group International in a report on Friday, August 21st.

Ascentage Pharma Group International Price Performance

NASDAQ AAPG opened at $14.69 on Friday. The company has a debt-to-equity ratio of 1.09, a quick ratio of 1.18 and a current ratio of 1.22. Ascentage Pharma Group International has a one year low of $14.45 and a one year high of $37.50. The firm's fifty day moving average is $16.55 and its two-hundred day moving average is $19.11.

Ascentage Pharma Group International (NASDAQ:AAPG - Get Free Report) last announced its earnings results on Wednesday, August 19th. The company reported ($0.65) EPS for the quarter. The firm had revenue of $22.24 million for the quarter. On average, analysts forecast that Ascentage Pharma Group International will post -2.42 earnings per share for the current fiscal year.

About Ascentage Pharma Group International

Ascentage Pharma Group International is a commercial-stage biopharmaceutical company focused on developing and commercializing treatments for cancer and other serious diseases.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.